IgGenix, Inc
329 Oyster Point Blvd., 3rd Floor
South San Francisco, CA 94080
650-491-9626
HR@IgGenix.com

Skip to content
This site uses cookies to provide you with a better browsing experience. More information can be found on the IgGenix Privacy Policy page. Accept
CLOSE
  • Home
  • Latest News
  • Technology
    • Platform
    • Pipeline
    • Publications
  • Team
    • Management
    • Scientific Co-Founders
    • Board of Directors
    • Scientific Advisory Board
  • Investors
  • Careers
  • Contact

Press Releases

  • March 2, 2023

    IgGenix Demonstrated Potential for Single-Cell RNA-Sequencing to Address Shellfish Allergies at the 2023 AAAAI Annual Meeting

  • February 6, 2023

    IgGenix Announces First Close of $40M Series B Financing to Accelerate Lead Antibody Program in Peanut Allergy

  • August 19, 2022

    How Re-Engineering Antibodies Can Prevent Allergies (Labiotech.eu)

  • July 1, 2022

    IgGenix Demonstrates Potential for Single-Cell RNA-Sequencing in Tree Nut Allergies

  • April 26, 2022

    IgGenix Announces Move of Headquarters to Lilly Gateway Labs in South San Francisco

  • February 23, 2022

    IgGenix Announces Presentation on Food Allergy Research at American Academy of Allergy, Asthma & Immunology Annual Meeting

  • July 27, 2021

    IgGenix Announces $25M in Series A1 Funding

  • June 24, 2021

    IgGenix Announces Jessica Grossman, M.D., as Chief Executive Officer

  • June 2, 2021

    IgGenix: Engineering Antibodies to Fight Food Allergies (Nature Biotechnology)

  • November 6, 2020

    IgGenix: Antibody Engineering for Food Allergies (BioCentury)

BACK

Posts navigation

Older posts
  • Home
  • Latest News
  • Technology
    • Platform
    • Pipeline
    • Publications
  • Team
    • Management
    • Scientific Co-Founders
    • Board of Directors
    • Scientific Advisory Board
  • Investors
  • Careers
  • Contact
©2023 IgGenix, Inc., All rights reserved. Privacy
  • LinkedIn